Encoding glucose control

Renova Therapeutics has licensed a gene therapy technology for Type II diabetes from the University of California San Diego that could control blood glucose levels for years with only a single injection. By discovering a new role for the paracrine peptide UCN2, the company believes it has a fresh angle on the long search to bypass the peaks and troughs of standard therapies.

Renova's lead product RT-100 (Ad5.hAC6), a Phase II gene therapy for congestive heart failure, is slated to enter a pivotal trial by year end. Now, the company is focusing on building its preclinical pipeline by using gene therapy to deliver paracrine factors...